A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Preserve Beta Cell Function in Participants Newly Diagnosed with Type 1 Diabetes Aged ≥1 to <36 Years (BARICADE-PRESERVE) (I4V-MC-JAJK (BARICADE-PRESERVE))

Principal Investigator

Prof Katharine Owen

Contact us

Email: diabetes.research1@ouh.nhs.uk

IRAS number

1012673